.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,242,270

« Back to Dashboard

Details for Patent: 8,242,270

Title:Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Abstract: The invention relates to processes for preparing compounds having the formula, ##STR00001## and crystalline forms thereof, wherein Ar is aryl or heteroaryl, L is an optional alkylene linker, and R.sub.2, R.sub.3, R.sub.4, and R.sub.5, are as defined in the specification herein, which compounds are useful as kinase inhibitors, in particular, inhibitors of protein tyrosine kinase and p38 kinase.
Inventor(s): Lajeunesse; Jean (Candiac, CA), DiMarco; John D. (East Brunswick, NJ), Galella; Michael (Kendall Park, NJ), Chidambaram; Ramakrishnan (Santa Clara, CA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Filing Date:Dec 23, 2008
Application Number:12/342,141
Claims:1. Crystalline butanol solvate of the compound of formula (IV) ##STR00062##

2. The compound of claim 1, characterized by unit cell parameters approximately equal to the following: Cell dimensions: a(.ANG.)=22.8102(6); b(.ANG.)=8.4691(3); c(.ANG.)=15.1436(5); .beta.=95.794(2); Volume=2910.5(2) .ANG..sup.3 Space group P2.sub.1/a Molecules/unit cell: 4 Density (calculated) (g/cm.sup.3): 1.283.

3. Crystalline ethanol solvate of the compound of formula (IV) ##STR00063##

4. The compound of claim 3, having unit cell parameters (at about -40.degree. C.) approximately equal to the following: a(.ANG.)=22.076(1); b(.ANG.)=8.9612(2); c(.ANG.)=16.8764(3); .beta.=114.783(1); Volume=3031.1(1) (.ANG..sup.3); Space group P2.sub.1/a Molecules/unit cell 4.

5. The compound of claim 3, which is characterized by an x-ray powder diffraction pattern (CuK.alpha. .lamda.=1.5418 .ANG. at a temperature of about 23.degree. C.) comprising four or more 2.theta. values selected from the group consisting of: 5.8.+-.0.2, 11.3.+-.0.2, 15.8.+-.0.2, 17.2.+-.0.2, 19.5.+-.0.2, 24.1.+-.0.2, 25.3.+-.0.2, and 26.2.+-.0.2.

6. Crystalline compound of formula (IV) ##STR00064## having unit cell parameters approximately equal to the following: a(.ANG.)=22.957(1); b(.ANG.)=8.5830(5); c(.ANG.)=13.803(3); .beta.=112.039(6); Volumer=2521.0(5) (.ANG..sup.3); Space group P2.sub.1/a Molecules/unit cell 4.

7. Crystalline compound of formula (IV) ##STR00065## which is characterized by an x-ray powder diffraction pattern (CuK.alpha. .lamda.=1.5418 .ANG. at a temperature of about 23.degree. C.) comprising four or more 2.theta. values selected from the group consisting of: 6.8.+-.0.2, 11.1.+-.0.2, 12.3.+-.0.2, 13.2.+-.0.2, 13.7.+-.0.2, 16.7.+-.0.2, 21.0.+-.0.2, 24.3.+-.0.2, and 24.8.+-.0.2.

8. Crystalline compound of formula (IV) ##STR00066## having unit cell parameters approximately equal to the following: a(.ANG.)=13.4916; b(.ANG.)=9.3992(2); c(.ANG.)=38.817(1); Volume=4922.4(3) (.ANG..sup.3); Space group Pbca.

9. Crystalline compound of formula (IV) ##STR00067## which is characterized by an x-ray powder diffraction pattern (CuK.alpha. .lamda.=1.5418 .ANG. at a temperature of about 23.degree. C.) comprising four or more 2.theta. values selected from the group consisting of: 8.0.+-.0.2, 9.7.+-.0.2, 11.2.+-.0.2, 13.3.+-.0.2, 17.5.+-.0.2, 18.9.+-.0.2, 21.0.+-.0.2, 22.0.+-.0.2.

10. The compound of claim 3, having unit cell parameters (at about -10.degree. C.) approximately equal to the following: a(.ANG.)=22.03(2); b(.ANG.)=9.20(1); c(.ANG.)=12.31(1); .beta.=93.49(6); Volume=2491(4) (.ANG..sup.3); Space group P2.sub.1/a Molecules/unit cell 4.

11. The compound of claim 3, which is characterized by an x-ray powder diffraction pattern (CuK.alpha. .lamda.=1.5418 .ANG. at a temperature of about 23.degree. C.) comprising four or more 2.theta. values selected from the group consisting of: 7.20.+-.0.2, 12.01.+-.0.2, 12.81.+-.0.2, 18.06.+-.0.2, 19.30.+-.0.2, and 25.24.+-.0.2.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc